The current financial score of Rhythm Pharmaceuticals Inc is 7.61. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 71.25M, representing a year-over-year increase of 46.91%, while its net profit experienced a year-over-year increase of 4.96%.
The current valuation score of Rhythm Pharmaceuticals Inc is 9.44. Its current P/E ratio is -31.58, which is -84.71% below the recent high of -4.83 and -20.21% above the recent low of -37.96.
The current earnings forecast score of Rhythm Pharmaceuticals Inc is 8.63. The average price target is 139.00, with a high of 160.00 and a low of 105.00.
The current price momentum score of Rhythm Pharmaceuticals Inc is 3.88. Currently, the stock price is trading between the resistance level at 110.47 and the support level at 91.86, making it suitable for range-bound swing trading.
The current institutional shareholding score of Rhythm Pharmaceuticals Inc is 10.00. The latest institutional shareholding proportion is 116.93%, representing a quarter-over-quarter increase of 4.50%. The largest institutional shareholder is PRIMECAP Management, holding a total of 3.17M shares, representing 0.21% of shares outstanding, with 17.91% decrease in holdings.
The current risk assessment score of Rhythm Pharmaceuticals Inc is 6.59. The company's beta value is 1.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.